Updates, advisories and surprises

(4:23 PM ET) SAN FRANCISCO (MarketWatch) -- Agilent Technologies Inc.
A, +0.70%
on Monday reported a fiscal fourth-quarter profit of $16 million, or 5 cents a share, on revenue of $1.81 billion. During the year-ago period, the testing and measurement-technology company earned $211 million, or 63 cents a share, on $1.72 billion in revenue. Excluding one-time items, Agilent earned 88 cents a share. Analysts surveyed by FactSet had forecast Agilent to earn 64 cents a share on sales of $1.81 billion. For its fiscal first quarter, Agilent estimates it will earn 39 cents to 43 cents a share, excluding one-time items, on sales in a range of $1.02 billion to $1.04 billion. Agilent shares were down slightly in after-hours trading.

Urban Outfitters' stock falls after profit, same-store sales miss

(4:12 PM ET) NEW YORK (MarketWatch) -- Urban Outfitter's stock
URBN, -1.64%
shed 4.9% in after-hours trade Monday, after the apparel retailer missed fiscal third-quarter profit and same-store sales expectations, citing disappointing results at its namesake stores. Net earnings for the quarter ended Oct. 31 declined to $47.1 million, or 35 cents a share, from $70.3 million, or 47 cents a share, in the year-earlier period, below the FactSet consensus analyst estimate of 41 cents a share. Net sales rose 5% to $814.5 million, above analyst forecasts of $811.2 million. Meanwhile, same-store sales fell 1%, compared with expectations that they would be flat, as a 7% decline in sales at Urban Outfitters stores offset a 15% increase at Free People and 2% growth at Anthropologie. The stock has lost 17% year to date through Monday, compared with a 2.5% gain in the SPDR S&P Retail ETF
XRT, -0.54%
and a 10% rise in the S&P 500
SPX, +0.27%

Pfizer's stock drops after profit outlook cut

(8:04 AM ET) NEW YORK (MarketWatch) -- Pfizer's stock
PFE, +2.89%
fell 1.6% in premarket trade Monday, after the blue-chip drug maker lowered its 2014 profit outlook following its agreement to team up with Germany's Merck KGaA to develop new cancer treatments. Pfizer now expects full-year earnings per share of $1.40 to $1.49, down from its previous guidance of $1.50 to $1.59. The outlook was cut because as part of the cancer treatment partnership, Pfizer will pay Merck KGaA an upfront payment of $850 million, and could pay milestone payments of up to $2 billion. Pfizer said the new earnings outlook doesn't reflect the impact of sharing future profit of Pfizer's Xalkori cancer treatment, which the companies will both promote in the U.S. Pfizer said that once it concludes its analysis of the profit exchange, the impact could reduce financial results by $250 million to $400 million. Pfizer's stock, a component of the Dow industrials, has lost 1% year to date through Friday, compared with a 6.4% gain in the Dow.

Tyson Foods shares slump as sales fall below estimates

(7:42 AM ET) NEW YORK (MarketWatch) -- Tyson Foods Inc. shares fell 4% in premarket trade Monday, after the chicken, beef, pork and prepared food company reported fiscal fourth-quarter sales that were below estimates. The company, which acquired Hillshire Brands earlier this year, said it had net income of $137 million, or 35 cents a share, in the quarter, down from $261 million, or 70 cents a share, in the year-earlier period. Adjusted per-share earnings came to 87 cents, ahead of the FactSet consensus of 76 cents. Sales climbed to $10.105 billion from $8.894 billion, but were below the FactSet consensus of $10.290 billion. Chief Executive Donnie Smith said the company is on track with the integration of Hillshire Brands and is expecting to meet its synergy targets of $225 million or more for fiscal 2015 and more than $500 million by the end of year three. The company is expected fiscal 2015 per-share earnings of $3.30 to $3.40. Shares have gained 21.5% in the year so far, while the S&P 500 has gained 10%.

Intraday Data provided by SIX Financial Information and subject to terms of use.
Historical and current end-of-day data provided by SIX Financial Information. Intraday data
delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc.
All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More
information on NASDAQ traded symbols and their current financial status. Intraday
data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S&P/Dow Jones Indices (SM)
from Dow Jones & Company, Inc. SEHK intraday data is provided by SIX Financial Information and is
at least 60-minutes delayed. All quotes are in local exchange time.